-
Good news for insomnia patients, CHMP recommends dual-acting orexin receptor antagonist Quviviq
Time of Update: 2022-04-22
The Lancet results showed that daridorexant 25 mg and 50 mg improved sleep outcomes, and daridorexant 50 mg also improved daytime function in patients with insomnia with a favorable safety profile .
-
CNS: A big market for sleep disorders, new domestic orexin drugs enter Phase 3 clinical trials
Time of Update: 2021-12-06
Chinese Adult Insomnia Diagnosis and Treatment Guidelines (2017 Edition); Chinese Journal of Neurology, 2018,51(5): 324-335; Sleep Disorder Group, Chinese Medical Association Neurology Branch, Chinese Medical Association Neurology Branch; https://mp .
-
Nat Commun : Zhang Jun group reveals the important role of the hypothalamus orexin nervous system in THE maintenance of REM sleep stability.
Time of Update: 2020-07-30
Zhang Jun, a research group in the Department of Physiology and Research at the Basic Medical College of the Army Military Medical University (formerly the Third Military Medical University), published a study in communications magazine entitled Orexin Signaling Modulates synced excitation in the sublaterodorsal tegmental quis to REM sleep, which was first clearly reported on the direct involvement of the hypothalamus orexin nervous system in rapid eye movement (REM) sleep regulation, and the resolution of the system's molecular and neuro-neuro-mechanism.
-
New medicine for insomnia! Dayvigo (lemborexant), a dual effect orexin receptor antagonist of Weicai, was approved by Japan!
Time of Update: 2020-01-26
January 26, 2020 / BIOON / -- Eisai recently announced that dayvigo (lemborexant) has been approved in Japan It is an orexin receptor antagonist discovered and developed by Eisai It is used to treat a
-
New medicine for insomnia! Phase III of ldayvigo (lemborexant), a dual effect orexin receptor antagonist of Weicai, significantly improved sleep quality!
Time of Update: 2019-12-28
December 28, 2019 / BIOON / -- Eisai, a Japanese pharmaceutical company, recently announced that the results of sunrise-1 (304 study), a key phase III head-on study for the treatment of insomnia by da
-
New medicine for insomnia! Dayvigo (lemborexant), a dual effect orexin receptor antagonist of Weicai, has been approved by the US FDA!
Time of Update: 2019-12-23
December 23, 2019 / BIOON / -- Japanese pharmaceutical company Eisai recently announced that the U.S Food and Drug Administration (FDA) has approved dayvigo (lemborexant), an orexin receptor antagonis
-
Nat Commun Orexin regulates central serotonin (5-HT) neurons to control peripheral glucose metabolism
Time of Update: 2021-10-01
Reverse fluorescence tracking showed that different groups of orexin neurons projected to DR or RPa, which further provided anatomical basis for Ox1R and Ox2R in 5-HT neurons to play different roles in peripheral glucose metabolism .